Resource Library
26 Results (showing 1 - 10)
Results sorted by updated date (newest first)
Results sorted by updated date (newest first)
Posted 4/26/2024 (updated 8/22/2024)
The Nitazenes Overview resource created by RCORP-TA describes what nitazenes are, how to determine if they are in your community, and how to prevent and respond to overdoses due to nitazenes. Additional resources are also provided to learn more about …
Posted 10/23/2023 (updated 3/27/2024)
The Reagan-Udall Foundation partnered with the Food and Drug Administration (FDA) for the " Mitigating Risks from Human Xylazine Exposure " virtual and in-person webinar that occurred early October 2023. This public meeting explored real-world experiences …
Posted 8/18/2023 (updated 3/26/2024)
The National Institute on Drug Abuse (NIDA) Center for the Clinical Trials Network (CCTN) held an event where health care professionals and federal partners discussed xylazine-related testing, treatment, and wound care. As the White House has deemed …
Posted 7/26/2023 (updated 3/28/2024)
Presenter(s): Stacey C. Sigmon, PhD, Professor, UVM Departments of Psychiatry and Psychological Science; Director, UVM Center on Rural Addiction Session Description: This presentation provided an overview of the (1) current U.S. prevalence of opioid abuse …
Posted 7/21/2023 (updated 3/28/2024)
The Office of National Drug Control Policy (ONDCP) released a plan in response to fentanyl being adulterated or associated with xylazine, which was declared as an emerging drug threat in April 2023. Due to the effect of combining these substances, people …
Posted 7/14/2023 (updated 3/28/2024)
The Centers for Disease Control and Prevention released data showing a significant increase – 276 percent in 21 jurisdictions from 2019 to 2022 – in overdose deaths involving Xylazine, a nonopioid sedative that’s been detected in illicitly manufactured …
Posted 5/16/2023 (updated 3/27/2024)
Xylazine, a veterinary tranquilizer not approved for human use, has been increasingly identified in parts of the U.S. illicit drug supply. Not only does xylazine escalate overdose risk, it is also associated with other risks and medical complications. …
Posted 4/11/2023 (updated 3/27/2024)
The first phase of the campaign created by the White House Office of National Drug Control Policy (ONDCP) and Ad Council was launched to education young people on the dangers of fentanyl and the life-saving effects of Naloxone, a medicine that reverses …
Posted 3/21/2023 (updated 3/27/2024)
Dr. Phillip Coffin discussed and reviewed the epidemiology of stimulant use, toxicities related to stimulants, and interventions. Learning Objectives: Explore epidemiology of stimulant use Describe toxicities of simulant use Identify interventions to …
Posted 3/14/2023 (updated 3/27/2024)
Xylazine is a non-opioid that is approved for animals, and not FDA-approved for humans. New York State's Department of Health provides information on what it is, sources and trends, effects, why people use it, why clinicians should be concerned, and other …